ストックスクリーナーアプリを入手
127.85
0.04%
-0.05
前日終値:
$127.90
開ける：
$128.07
24時間の取引高:
3.07M
Relative Volume:
1.43
時価総額：
$6.55B
収益：
$434.41M
当期純損益:
$-128.05M
株価収益率:
-60.59
EPS:
-2.11
ネットキャッシュフロー:
$-250.52M
1週間 パフォーマンス:
+26.15%
1か月 パフォーマンス:
+28.93%
6か月 パフォーマンス:
+33.22%
1年 パフォーマンス:
+22.44%
1日の値動き範囲:
$127.77
$128.07
1週間の範囲:
$127.43
$128.24
52週間の値動き範囲:
$73.04
$128.24
Blueprint Medicines Corp Stock (BPMC) Company Profile
名前
Blueprint Medicines Corp
セクター
電話
617-374-7580
住所
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
127.85 | 6.55B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-03-20 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-03-18 | 開始されました | Wolfe Research | Outperform |
| 2025-03-17 | 開始されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-14 | 開始されました | JP Morgan | Overweight |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-05-06 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 繰り返されました | Needham | Buy |
| 2023-07-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-11-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2022-07-08 | 開始されました | Oppenheimer | Outperform |
| 2022-06-27 | 開始されました | Wells Fargo | Underweight |
| 2022-06-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-06-01 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-01 | 開始されました | Citigroup | Neutral |
| 2022-02-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | アップグレード | Stifel | Hold → Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 再開されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-11-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-02 | ダウングレード | Jefferies | Buy → Hold |
| 2020-10-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Equal Weight |
| 2020-03-17 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-11-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-09-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 開始されました | Piper Jaffray | Neutral |
| 2019-08-15 | 再開されました | Raymond James | Mkt Perform |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-05-23 | 再開されました | Goldman | Buy |
| 2019-04-03 | 開始されました | Morgan Stanley | Overweight |
| 2018-09-25 | 開始されました | Leerink Partners | Outperform |
| 2017-12-11 | 繰り返されました | Goldman | Buy |
すべてを表示
Blueprint Medicines Corp (BPMC) 最新ニュース
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta - Benzinga
Blueprint Medicines (BPMC): Morgan Stanley Raises Price Target | BPMC Stock News - GuruFocus
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal - TradingView
Citigroup Upgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq
Sanofi to acquire Blueprint Medicines for about $9.1B - Drug Store News
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | - GuruFocus
Blueprint Medicines (BPMC) Sees Price Target Increase Amid Acquisition News | BPMC Stock News - GuruFocus
Sanofi to buy Blueprint Medicines for $9.1B - MSN
Blueprint Medicines (BPMC) Target Price Increased Following Acqu - GuruFocus
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform - Insider Monkey
Kalkine: How Is Blueprint Medicines (NASDAQ:BPMC) Positioned Within the Nasdaq Composite Framework? - Kalkine Media
Sanofi to Buy Blueprint for $9.1 Billion Equity Value - MSN
Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSN
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly | BPMC Stock News - GuruFocus
Citi upgrades Blueprint Medicines stock rating after Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Sees Upgrade and Acquisition by Sanofi | BPMC Stock News - GuruFocus
Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition - MSN
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines CorporationBPMC - Business Wire
Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen - Insider Monkey
Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform - Insider Monkey
Blueprint Medicines (BPMC) Downgraded Following Acquisition News - GuruFocus
Blueprint Medicines (BPMC) Downgraded Following Acquisition News | BPMC Stock News - GuruFocus
Blueprint Medicines downgraded to Neutral from Buy at Guggenheim - TipRanks
Sanofi to acquire Blueprint for up to $9.5B - Pharma Voice
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC S - GuruFocus
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Wolfe Research | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Stephens & Co. | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Downgraded Following Acquisition Deal | BPMC Stock News - GuruFocus
Sanofi to acquire US biotech firm Blueprint for up to $9.5bn - World Pharmaceutical Frontiers
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Pr - GuruFocus
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition - Investing.com
TD Cowen cuts Blueprint Medicines stock rating following Sanofi acquisition By Investing.com - Investing.com Nigeria
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition By Investing.com - Investing.com India
JPMorgan downgrades Blueprint Medicines stock after Sanofi acquisition By Investing.com - Investing.com Nigeria
TD Cowen cuts Blueprint Medicines stock rating following Sanofi acquisition - Investing.com
Blueprint Medicines downgraded to Neutral from Outperform at Wedbush - TipRanks
Blueprint Medicines stock hits all-time high of $128.04 By Investing.com - Investing.com South Africa
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday - Yahoo
Blueprint Medicines downgraded to Hold from Buy at Needham - TipRanks
Correction: French Drugmaker Sanofi to Buy US-based Blueprint Medicines for $9.5 Billion - marketscreener.com
JP Morgan Downgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq
Blueprint Medicines Stock Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith - MSN
Sanofi to expand immunology offerings with Blueprint Medicines - Pharmaceutical Technology
Market Today: Sanofi Acquires Blueprint Medicines, BioNTech Part - GuruFocus
Blueprint Medicines downgraded to Hold from Buy at TD Cowen - TipRanks
Blueprint Medicines (BPMC) Downgraded After Acquisition Announce - GuruFocus
Weil Advises Sanofi in its $9.5 Billion Acquisition of Blueprint Medicines - Weil
Blueprint Medicines (BPMC) Downgraded After Sanofi's Acquisition Announcement | BPMC Stock News - GuruFocus
Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila - TipRanks
Market Today: Sanofi Acquires Blueprint Medicines, BioNTech Partners with Bristol Myers - GuruFocus
Blueprint Medicines Corp (BPMC) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):